 Abstract Alzheimer's disease, AD, can be diagnosed through the presence of certain biomarkers such as beta amyloid, A, and tau proteins. These biomarkers are measured using mass spectrometry, but this technique has limitations due to its high cost and complexity. In order to overcome these issues, researchers have developed a new method called selective reaction monitoring mass spectrometry, SIMMS, which uses isotope-labeled standards to measure the levels of various proteins in cerebrospinal fluid, CSF. The results show that SIMMS is highly accurate and precise, allowing for the detection of multiple proteins associated with AD. Additionally, the method was able to differentiate between healthy individuals and those suffering from AD, suggesting that it may be useful for early diagnosis of the disease. This article was authored by Caroline M. Watson, Eric B. Dammer, Linyan Ping, and others.